SI2470168T1 - Postopki za preprečevanje in zdravljenje možganske ishemije - Google Patents
Postopki za preprečevanje in zdravljenje možganske ishemije Download PDFInfo
- Publication number
- SI2470168T1 SI2470168T1 SI201031644T SI201031644T SI2470168T1 SI 2470168 T1 SI2470168 T1 SI 2470168T1 SI 201031644 T SI201031644 T SI 201031644T SI 201031644 T SI201031644 T SI 201031644T SI 2470168 T1 SI2470168 T1 SI 2470168T1
- Authority
- SI
- Slovenia
- Prior art keywords
- composition
- tocotrienolquinone
- alpha
- treatment
- stereoisomer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (16)
- POSTOPKI ZA PREPREČEVANJE IN ZDRAVLJENJE MOŽGANSKE ISHEMIJE EP 2 470 168 B1 PATENTNI ZAHTEVKI1. Sestavek za uporabo pri zdravljenju, preprečevanju in/ali izboljšanju nevronske poškodbe, povezane z možganskim ishemičnim dogodkom ali hipoksijo pri sesalcu, ki potrebuje takšno zdravljenje, pri čemer omenjeni sestavek vsebuje učinkovito količino tokotrienol kinona, izbranega iz skupine, ki jo sestavljajo alfa-tokotrienol-kinon, beta-tokotrienol-kinon, gama-tokotrienol-kinon in delta-tokotrienol-kinon ali njihove mešanice ali ena sama stereoizomera ali mešanica njihovih stereoizomer; s pridržkom, da navedeni osebek ne trpi zaradi mitohondrijske bolezni.
- 2. Sestavek po zahtevku 1, za uporabo, kot je definiran v omenjenem zahtevku, kjer sestavek obsega učinkovito količino alfa-tokotrienol-kinona ali katerekoli stereoizomere ali mešanice stereoizomer.
- 3. Sestavek po zahtevku 1 za uporabo, kot je definiran v omenjenem zahtevku, kjer je cerebralni ishemični dogodek sekundaren za okluzijo cerebralne vaskulature.
- 4. Sestavek po zahtevku 3, za uporabo, kot je definiran v omenjenem zahtevku, pri čemer je okluzija posledica tromboembolije.
- 5. Sestavek po zahtevku 1 za uporabo, kot je definiran v omenjenem zahtevku, pri čemer je cerebralna ishemija posledica krčev koronarne vaskulature.
- 6. Sestavek po zahtevku 1, za uporabo, kot je definiran v omenjenem zahtevku, pri čemer je cerebralni ishemični dogodek sekundaren za prenehanje srčne funkcije, kardiopulmonalni obvodni postopek ali hemoragični dogodek v cerebralni vaskularni bolezni.
- 7. Sestavek po zahtevku 2, za uporabo, kot je definiran v omenjenem zahtevku, kjer omenjeni tokotrienol kinonski sestavek obsega vsaj okoli 65% alfa-tokotrienol-kvinona.
- 8. Sestavek po zahtevku 1 za uporabo, kot je definiran v omenjenem zahtevku, kjer navedeni sestavek dodatno obsega farmacevtsko sprejemljiv nosilec.
- 9. Sestavek po zahtevku 1 za uporabo, kot je definiran v omenjenem zahtevku, pri čemer se navedeni sestavek daje peroralno.
- 10. Sestavek po zahtevku 1, za uporabo, kot je definiran v omenjenem zahtevku, pri čemer se navedeni sestavek daje parenteralno.
- 11. Sestavek po zahtevku 2 za uporabo, kot je definiran v omenjenem zahtevku, kjer navedeni sestavek vsebuje alfa-tokotrienol kinon v količini od okoli 1 do okoli 1000 mg na kg telesne mase omenjenega sesalca.
- 12. Sestavek po zahtevku 2, za uporabo, kot je definiran v omenjenem zahtevku, kjer navedeni sestavek vsebuje alfa-tokotrienol kinon v količini od okoli 1 do okoli 50 mg na kg telesne mase omenjenega sesalca.
- 13. Sestavek po zahtevku 1, za uporabo, kot je definiran v omenjenem zahtevku, kjer je omenjena nevronska poškodba izbrana izmed smrti nevronske celice, celotnega volumna možganskega infarkta, možganske ishemične poškodbe, edemov možganskega tkiva in kognitivne disfunkcije.
- 14. Sestavek za uporabo pri zdravljenju in/ali izboljšanju cerebralnega ishemičnega dogodka ali hipoksije pri sesalcu, ki potrebuje takšno zdravljenje, pri čemer navedeni sestavek vsebuje učinkovito količino tokotrienol-kinona, izbranega iz skupine, ki jo sestavljajo alfa-tokotrienol-kinon, beta -tokotrienol-kinon, gama-tokotrienol-kinon in delta-tokotrienol-kinon ali njihove mešanice, ali ena sama stereoizomera ali mešanica njihovih stereoizomer; s pridržkom, da navedeni osebek ne trpi zaradi mitohondrijske bolezni, pri kateri je možganska kap eden od simptomov mitohondrijske bolezni.
- 15. Sestavek po zahtevku 14 za uporabo, kot je definiran v omenjenem zahtevku, kjer sestavek vsebuje učinkovito količino alfa-tokotrienol-kvinona ali katerekoli stereoizomere ali mešanice stereoizomer.
- 16. Sestavek po kateremkoli od zahtevkov 1-15, za uporabo, kot je definiran v omenjenem zahtevku, kjer je alfa-tokotrienol kinon ali stereoizomer ali zmesi njegovih stereoizomerov edina aktivna sestavina, prisotna v učinkoviti količini v sestavku.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27526909P | 2009-08-26 | 2009-08-26 | |
EP10747777.0A EP2470168B1 (en) | 2009-08-26 | 2010-08-24 | Methods for the prevention and treatment of cerebral ischemia |
PCT/US2010/046503 WO2011025785A1 (en) | 2009-08-26 | 2010-08-24 | Methods for the prevention and treatment of cerebral ischemia |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2470168T1 true SI2470168T1 (sl) | 2018-05-31 |
Family
ID=42983642
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201031644T SI2470168T1 (sl) | 2009-08-26 | 2010-08-24 | Postopki za preprečevanje in zdravljenje možganske ishemije |
Country Status (17)
Country | Link |
---|---|
US (3) | US20110207828A1 (sl) |
EP (1) | EP2470168B1 (sl) |
JP (2) | JP5785546B2 (sl) |
CN (1) | CN102647981B (sl) |
AU (1) | AU2010286704B2 (sl) |
BR (1) | BR112012004167A2 (sl) |
CA (1) | CA2772294C (sl) |
DK (1) | DK2470168T3 (sl) |
EA (1) | EA028677B1 (sl) |
ES (1) | ES2663709T3 (sl) |
HU (1) | HUE037592T2 (sl) |
MX (1) | MX337990B (sl) |
NO (1) | NO2470168T3 (sl) |
PL (1) | PL2470168T3 (sl) |
PT (1) | PT2470168T (sl) |
SI (1) | SI2470168T1 (sl) |
WO (1) | WO2011025785A1 (sl) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7514461B2 (en) | 2003-09-19 | 2009-04-07 | Edison Pharmaceuticals, Inc. | Chroman derivatives |
EA016226B1 (ru) | 2005-06-01 | 2012-03-30 | Эдисон Фармасьютикалз, Инк. | Редокс-активные терапевтические соединения для лечения митохондриальных заболеваний |
EP1986636B1 (en) | 2006-02-22 | 2013-04-24 | Edison Pharmaceuticals, Inc. | Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases |
DK2220030T3 (en) | 2007-11-06 | 2016-04-11 | Edison Pharmaceuticals Inc | 4- (P-QUINONYL) -2-HYDROXYBUTANAMIDDERIVATER TO TREAT mitochondrial |
CA2708961C (en) * | 2008-01-08 | 2017-03-28 | Edison Pharmaceuticals, Inc. | (het)aryl-p-quinone derivatives for treatment of mitochondrial diseases |
WO2009111576A2 (en) | 2008-03-05 | 2009-09-11 | Edison Pharmaceuticals, Inc. | 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES |
US8716486B2 (en) * | 2008-06-25 | 2014-05-06 | Edison Pharmaceuticals, Inc. | 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases |
JP2012502064A (ja) | 2008-09-10 | 2012-01-26 | エジソン ファーマシューティカルズ, インコーポレイテッド | 酸化還元活性治療剤を用いての広汎性発達障害の処置 |
EP2362726B1 (en) | 2008-10-14 | 2018-08-08 | Bioelectron Technology Corporation | Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells |
SI2963006T1 (sl) | 2008-10-28 | 2019-01-31 | Bioelectron Technology Corporation | Sestavek vsebujoč alfa-tokotrienol kinon in njegove vmesne povezave |
ES2662051T3 (es) | 2009-04-28 | 2018-04-05 | Bioelectron Technology Corporation | Tratamiento de neuropatía óptica hereditaria de Leber y atrofia óptica dominante con tocotrienol quinonas |
WO2011082355A1 (en) * | 2009-12-31 | 2011-07-07 | Edison Pharmaceuticals, Inc. | Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones |
WO2011137126A1 (en) * | 2010-04-27 | 2011-11-03 | Edison Pharmaceuticals, Inc. | Formulations of quinones for the treatment of ophthalmic diseases |
WO2012174286A1 (en) | 2011-06-14 | 2012-12-20 | Edison Pharmaceuticals, Inc. | Catechol derivatives for treatment of oxidative stress diseases |
CA2842486C (en) | 2011-07-19 | 2022-09-06 | Edison Pharmaceuticals, Inc. | Methods for oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols |
GB201117808D0 (en) * | 2011-10-14 | 2011-11-30 | Siemens Medical Solutions | SUV correction following dose infiltration |
JP6117907B2 (ja) | 2012-03-19 | 2017-04-19 | シダラ セラピューティクス インコーポレーテッド | エキノキャンディン系化合物のための投与レジメン |
JP6393684B2 (ja) * | 2012-09-07 | 2018-09-19 | バイオエレクトロン テクノロジー コーポレイション | 個体のレドックス状態の調節において使用するためのキノン誘導体 |
BR112015010703B1 (pt) * | 2012-11-13 | 2021-02-17 | Invictus Biotechnology Pty Ltd | uso de uma composição farmacêutica e composição farmacêutica |
US9670170B2 (en) | 2013-03-15 | 2017-06-06 | Bioelectron Technology Corporation | Resorufin derivatives for treatment of oxidative stress disorders |
WO2014145116A2 (en) | 2013-03-15 | 2014-09-18 | Edison Pharmaceuticals, Inc. | Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders |
US9296712B2 (en) | 2013-03-15 | 2016-03-29 | Edison Pharmaceuticals, Inc. | Resorufin derivatives for treatment of oxidative stress disorders |
US9868711B2 (en) | 2013-03-15 | 2018-01-16 | Bioelectron Technology Corporation | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
RU2578451C1 (ru) * | 2014-12-09 | 2016-03-27 | Государственное Бюджетное Образовательное Учреждение Высшего Профессионального Образования "Амурская Государственная Медицинская Академия" Министерства Здравоохранения Российской Федерации | Способ повышения устойчивости головного мозга к ишемии во время реконструктивных операций на брахиоцефальных артериях |
JP6810692B2 (ja) | 2014-12-16 | 2021-01-06 | ピーティーシー セラピューティクス, インコーポレイテッド | (r)−2−ヒドロキシ−2−メチル−4−(2,4,5−トリメチル−3,6−ジオキソシクロヘキサ−1,4−ジエニル)ブタンアミドの多形性形態および非晶質形態 |
WO2017106786A1 (en) | 2015-12-16 | 2017-06-22 | Bioelectron Technology Corporation | Improved methods for enriching alpha-tocotrienol from mixed tocol compositions |
WO2017106803A1 (en) | 2015-12-17 | 2017-06-22 | Bioelectron Technology Corporation | Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
EP3430400B1 (en) | 2016-03-16 | 2023-06-21 | Cidara Therapeutics, Inc. | Dosing regimens for treatment of fungal infections |
US10707531B1 (en) | 2016-09-27 | 2020-07-07 | New Dominion Enterprises Inc. | All-inorganic solvents for electrolytes |
JP2018083799A (ja) | 2016-11-15 | 2018-05-31 | バイオエレクトロン テクノロジー コーポレイション | 2−置換アミノ−ナフト[1,2−d]イミダゾール−5−オン化合物またはその製薬学上許容される塩 |
CA3069423A1 (en) | 2017-07-12 | 2019-01-17 | Cidara Therapeutics, Inc. | Formulations for the treatment of fungal infections |
JP2021529835A (ja) * | 2018-07-03 | 2021-11-04 | ベンチュリス セラピューティクス, インク.Venturis Therapeutics, Inc. | 脳卒中を治療するための組成物及び方法 |
PL3866772T3 (pl) | 2018-10-17 | 2024-04-08 | Ptc Therapeutics, Inc. | 2,3,5-trimetylo-6-nonylocykloheksa-2,5-dieno-1,4-dion do hamowania i leczenia alfa-synukleinopatii, tauopatii i innych zaburzeń |
KR20220078644A (ko) | 2019-10-04 | 2022-06-10 | 스텔스 바이오테라퓨틱스 인코포레이티드 | 미토콘드리아 질환 치료를 위한 바티퀴논의 퀴논-, 히드로퀴논- 및 나프토퀴논-유사체 |
EP4045526A4 (en) * | 2019-10-17 | 2023-11-15 | The Penn State Research Foundation | REGENERATION OF FUNCTIONAL NEURONS FOR THE TREATMENT OF HEMORRHAGIC STROKE |
CN113066113B (zh) * | 2021-04-27 | 2022-01-11 | 河北医科大学第二医院 | 自发性高血压大鼠脑模板和地图集的构建方法及设备 |
WO2023283466A1 (en) | 2021-07-08 | 2023-01-12 | Ptc Therapeutics, Inc. | Pharmaceutical compositions comprising 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5938203B2 (ja) * | 1976-04-26 | 1984-09-14 | エーザイ株式会社 | 補酵素qを主成分とする脳循環障害治療剤 |
US5872108A (en) * | 1995-03-06 | 1999-02-16 | Interneuron Pharmaceuticals, Inc. | Reduction of infarct volume using citicoline |
US6232060B1 (en) * | 1996-01-19 | 2001-05-15 | Galileo Laboratories, Inc. | Assay system for anti-stress agents |
US5801159A (en) * | 1996-02-23 | 1998-09-01 | Galileo Laboratories, Inc. | Method and composition for inhibiting cellular irreversible changes due to stress |
FR2753098B1 (fr) * | 1996-09-06 | 1998-11-27 | Sod Conseils Rech Applic | Composition pharmaceutique comprenant au moins un inhibiteur de no synthase et au moins un piegeur des formes reactives de l'oxygene |
WO1999025336A1 (en) | 1997-11-17 | 1999-05-27 | Lipogenics, Inc. | Methods for preventing restenosis using tocotrienols |
US6048891A (en) * | 1998-12-17 | 2000-04-11 | Loma Linda University Medical Center | Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease |
WO2000078296A2 (en) | 1999-06-17 | 2000-12-28 | Basf Aktiengesellschaft | Tocotrienol and/or tocotrienol derivatives for the treatment or prophylaxis of glutamate- and/or calcium-induced disorders |
US6528042B1 (en) * | 1999-10-08 | 2003-03-04 | Galileo Laboratories, Inc. | Compositions of flavonoids for use as cytoprotectants and methods of making and using them |
US6426362B1 (en) * | 1999-10-08 | 2002-07-30 | Galileo Laboratories, Inc. | Formulations of tocopherols and methods of making and using them |
US6346544B2 (en) * | 2000-03-02 | 2002-02-12 | Oklahoma Medical Research Foundation | Desmethyl tocopherols for protecting cardiovascular tissue |
DE10034233A1 (de) * | 2000-07-14 | 2002-01-24 | Basf Ag | Tocotrienolchinon-Cyclisierungsprodukte |
AU2002239748A1 (en) * | 2000-12-15 | 2002-06-24 | Galileo Laboratories, Inc. | Use of tocopherol, metabolites or derivatives thereof or flavonoid metabolites or derivatives thereof in the manufacture of a medicament for the treatment of tissue ischemia |
US7034054B2 (en) * | 2000-12-15 | 2006-04-25 | Galileo Pharmaceuticals, Inc. | Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols |
US6608196B2 (en) * | 2001-05-03 | 2003-08-19 | Galileo Pharmaceuticals, Inc. | Process for solid supported synthesis of pyruvate-derived compounds |
JP2005501094A (ja) * | 2001-08-21 | 2005-01-13 | ガリレオ ファーマシューティカルズ, インコーポレイティド | トコフェロール富化組成物および炎症性症状の回復 |
EP1450787A4 (en) * | 2001-11-15 | 2006-01-25 | Galileo Pharmaceuticals Inc | FORMULATIONS AND METHODS FOR THE TREATMENT OR AMELIORATION OF INFLAMMATORY CONDITIONS |
US20040152764A1 (en) * | 2001-12-14 | 2004-08-05 | Miller Guy M. | Compositions and methods for the prevention and treatment of cerebral ischemia |
US7078541B2 (en) * | 2002-02-07 | 2006-07-18 | Galileo Pharmaceuticals, Inc. | Benzofuran derivatives |
US6653346B1 (en) * | 2002-02-07 | 2003-11-25 | Galileo Pharmaceuticals, Inc. | Cytoprotective benzofuran derivatives |
CA2504334A1 (en) * | 2002-10-30 | 2004-05-21 | Galileo Pharmaceuticals, Inc. | Identifying therapeutic compounds based on their physical-chemical properties |
US7514461B2 (en) * | 2003-09-19 | 2009-04-07 | Edison Pharmaceuticals, Inc. | Chroman derivatives |
US7393662B2 (en) * | 2004-09-03 | 2008-07-01 | Centocor, Inc. | Human EPO mimetic hinge core mimetibodies, compositions, methods and uses |
EA016226B1 (ru) * | 2005-06-01 | 2012-03-30 | Эдисон Фармасьютикалз, Инк. | Редокс-активные терапевтические соединения для лечения митохондриальных заболеваний |
ES2823728T3 (es) * | 2005-09-15 | 2021-05-10 | Ptc Therapeutics Inc | Variantes de cola de agentes terapéuticos con actividad redox para el tratamiento de enfermedades mitocondriales y otras afecciones y la modulación de biomarcadores de energía |
EP1986636B1 (en) * | 2006-02-22 | 2013-04-24 | Edison Pharmaceuticals, Inc. | Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases |
AU2008205263A1 (en) * | 2007-01-10 | 2008-07-17 | Edison Pharmaceuticals, Inc. | Treatment of respiratory chain disorders using compounds having erythropoietin or thrombopoietin activity |
DK2220030T3 (en) * | 2007-11-06 | 2016-04-11 | Edison Pharmaceuticals Inc | 4- (P-QUINONYL) -2-HYDROXYBUTANAMIDDERIVATER TO TREAT mitochondrial |
EP2242506A4 (en) * | 2008-01-07 | 2011-12-28 | Janssen Biotech Inc | METHOD FOR THE TREATMENT OF ERYTHROPOIETIN HYPORESPONSE ANIMALS |
CA2708961C (en) * | 2008-01-08 | 2017-03-28 | Edison Pharmaceuticals, Inc. | (het)aryl-p-quinone derivatives for treatment of mitochondrial diseases |
US20110046156A1 (en) * | 2008-03-05 | 2011-02-24 | Miller Guy M | Treatment of hearing and balance impairments with redox-active therapeutics |
WO2009111576A2 (en) * | 2008-03-05 | 2009-09-11 | Edison Pharmaceuticals, Inc. | 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES |
CA2723621A1 (en) * | 2008-05-15 | 2009-11-19 | Edison Pharmaceuticals, Inc | Treatment of hearing and balance impairments using compounds having erythropoietin activity |
EA201001814A1 (ru) * | 2008-05-22 | 2011-04-29 | Эдисон Фармасьютикалз, Инк. | Лечение митохондриальных заболеваний миметиками эритропоэтина |
US8716486B2 (en) * | 2008-06-25 | 2014-05-06 | Edison Pharmaceuticals, Inc. | 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases |
WO2010005989A1 (en) * | 2008-07-09 | 2010-01-14 | Edison Pharmaceuticals, Inc. | Dermatological compositions with anti-aging and skin even-toning properties |
US20100029784A1 (en) * | 2008-07-30 | 2010-02-04 | Hinman Andrew W | Naphthoquinone compositions with anti-aging, anti-inflammatory and skin even-toning properties |
JP2012502064A (ja) * | 2008-09-10 | 2012-01-26 | エジソン ファーマシューティカルズ, インコーポレイテッド | 酸化還元活性治療剤を用いての広汎性発達障害の処置 |
EP2362726B1 (en) * | 2008-10-14 | 2018-08-08 | Bioelectron Technology Corporation | Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells |
SI2963006T1 (sl) * | 2008-10-28 | 2019-01-31 | Bioelectron Technology Corporation | Sestavek vsebujoč alfa-tokotrienol kinon in njegove vmesne povezave |
ES2662051T3 (es) * | 2009-04-28 | 2018-04-05 | Bioelectron Technology Corporation | Tratamiento de neuropatía óptica hereditaria de Leber y atrofia óptica dominante con tocotrienol quinonas |
CA2760357A1 (en) * | 2009-04-28 | 2010-11-04 | Ampere Life Sciences, Inc. | Topical, periocular, or intraocular use of tocotrienols for the treatment of ophthalmic diseases |
WO2010126909A1 (en) * | 2009-04-28 | 2010-11-04 | Edison Pharmaceuticals, Inc. | Formulation of tocotrienol quinones for the treatment of ophthalmic diseases |
MX2011013558A (es) * | 2009-06-25 | 2012-04-30 | Ampere Life Sciences Inc | Tratamiento del trastorno pervasivo del desarrollo con tocotrienoles o extractos de tocotrienoles enriquecidos. |
WO2011082355A1 (en) * | 2009-12-31 | 2011-07-07 | Edison Pharmaceuticals, Inc. | Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones |
CA2795726A1 (en) * | 2010-04-06 | 2011-10-13 | Edison Pharmaceuticals, Inc. | Treatment of ataxia telangiectasia |
WO2011137126A1 (en) * | 2010-04-27 | 2011-11-03 | Edison Pharmaceuticals, Inc. | Formulations of quinones for the treatment of ophthalmic diseases |
WO2012009271A1 (en) * | 2010-07-14 | 2012-01-19 | Penwest Pharmaceuticals Co. | Methods of providing anticoagulation effects in subjects |
US20120295985A1 (en) * | 2010-11-19 | 2012-11-22 | Miller Guy M | Methods for improving blood glucose control |
-
2010
- 2010-08-24 ES ES10747777.0T patent/ES2663709T3/es active Active
- 2010-08-24 EP EP10747777.0A patent/EP2470168B1/en active Active
- 2010-08-24 DK DK10747777.0T patent/DK2470168T3/en active
- 2010-08-24 AU AU2010286704A patent/AU2010286704B2/en not_active Ceased
- 2010-08-24 CA CA2772294A patent/CA2772294C/en active Active
- 2010-08-24 US US12/862,705 patent/US20110207828A1/en not_active Abandoned
- 2010-08-24 JP JP2012526918A patent/JP5785546B2/ja not_active Expired - Fee Related
- 2010-08-24 EA EA201200355A patent/EA028677B1/ru not_active IP Right Cessation
- 2010-08-24 WO PCT/US2010/046503 patent/WO2011025785A1/en active Application Filing
- 2010-08-24 CN CN201080048363.2A patent/CN102647981B/zh not_active Expired - Fee Related
- 2010-08-24 PL PL10747777T patent/PL2470168T3/pl unknown
- 2010-08-24 SI SI201031644T patent/SI2470168T1/sl unknown
- 2010-08-24 HU HUE10747777A patent/HUE037592T2/hu unknown
- 2010-08-24 PT PT107477770T patent/PT2470168T/pt unknown
- 2010-08-24 NO NO10747777A patent/NO2470168T3/no unknown
- 2010-08-24 MX MX2012002374A patent/MX337990B/es active IP Right Grant
- 2010-08-24 BR BR112012004167A patent/BR112012004167A2/pt not_active Application Discontinuation
-
2015
- 2015-02-16 JP JP2015027506A patent/JP2015091899A/ja active Pending
-
2016
- 2016-02-10 US US15/040,961 patent/US20170007553A1/en not_active Abandoned
-
2018
- 2018-08-09 US US16/100,062 patent/US20180344667A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2470168B1 (en) | 2018-01-31 |
US20110207828A1 (en) | 2011-08-25 |
EA201200355A1 (ru) | 2012-07-30 |
ES2663709T3 (es) | 2018-04-16 |
CA2772294A1 (en) | 2011-03-03 |
JP2015091899A (ja) | 2015-05-14 |
DK2470168T3 (en) | 2018-05-07 |
US20180344667A1 (en) | 2018-12-06 |
NO2470168T3 (sl) | 2018-06-30 |
BR112012004167A2 (pt) | 2016-03-29 |
CN102647981A (zh) | 2012-08-22 |
CA2772294C (en) | 2018-08-21 |
US20170007553A1 (en) | 2017-01-12 |
MX337990B (es) | 2016-03-30 |
HUE037592T2 (hu) | 2018-09-28 |
JP5785546B2 (ja) | 2015-09-30 |
AU2010286704B2 (en) | 2016-10-20 |
JP2013503168A (ja) | 2013-01-31 |
PL2470168T3 (pl) | 2018-06-29 |
EA028677B1 (ru) | 2017-12-29 |
PT2470168T (pt) | 2018-03-28 |
CN102647981B (zh) | 2016-09-28 |
MX2012002374A (es) | 2012-04-10 |
AU2010286704A1 (en) | 2012-03-22 |
EP2470168A1 (en) | 2012-07-04 |
WO2011025785A1 (en) | 2011-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI2470168T1 (sl) | Postopki za preprečevanje in zdravljenje možganske ishemije | |
JP2013503168A5 (sl) | ||
CO2023000199A2 (es) | Péptidos funcionalizados como agentes antivirales | |
AR088195A1 (es) | Composiciones farmaceuticas de n-metil-2-[3-(e)-2-piridin-2-il-vinil)-1h-indazol-6-ilsulfanil]-benzamida | |
US20170360798A1 (en) | Anavex2-73 and certain anticholinesterase inhibitors composition and method for neuroprotection | |
MY156858A (en) | Low-oil pharmaceutical emulsion compositions comprising progestogen | |
WO2009082819A8 (en) | Novel lupane derivatives | |
WO2009082818A8 (en) | Novel c-21-keto lupane derivatives preparation and use thereof | |
AR085662A1 (es) | Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia | |
BRPI0511967B8 (pt) | derivados de 5-amino-2,4,7-trioxo-3,4,7,8-tetrahidro-2h-pirido[2,3-d] pirimidina, seu uso e composição farmacêutica que os compreende | |
BR112014015197A8 (pt) | agentes antivirais de hepatite b | |
GT200000184A (es) | Composiciones para facilitar el crecimiento de la piel y metodos y articulos que la emplean. | |
US20080171709A1 (en) | Pharmaceutical Composition Comprising An Antiviral Agent, An Antitumoral Agent Or An Antiparasitic Agent, And An Active Agent Selected Among Carveol, Thymol, Eugenol, Borneol,And Carvacrol | |
JP2014526541A5 (sl) | ||
MX2020010907A (es) | Mejora de suministro de agentes activos lipofilicos a traves de la barrera hematoencefalica y metodos para tratar trastornos del sistema nervioso central. | |
UY32833A (es) | Antagonistas dp2 y usos del mismo | |
JP2016521717A (ja) | 5環性トリテルペンとヒドロキシチロソール及びその誘導体との組み合わせ | |
AR055591A1 (es) | Una composicion topica protectora de la piel y su uso | |
EP2870161A1 (en) | Oxabicycloheptanes and oxabicycloheptenes for the treatment of reperfusion injury | |
EP2857017A2 (en) | Use of dimiracetam in the treatment of chronic pain | |
AR064543A1 (es) | Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales | |
JPWO2020109806A5 (sl) | ||
CN100357312C (zh) | 赖氨酸七叶皂苷及其制备方法和其用途 | |
HRP20230634T1 (hr) | Pripravci za liječenje oftalmoloških stanja | |
GB2594907A (en) | Composition |